Avalo Therapeutics AVTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's total current liabilities?
- Avalo Therapeutics (AVTX) reported total current liabilities of $11.6M in Q1 2026.
- How has Avalo Therapeutics's total current liabilities changed year-over-year?
- Avalo Therapeutics's total current liabilities increased by 106.6% year-over-year, from $5.62M to $11.6M.
- What is the long-term trend for Avalo Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total current liabilities has grown at a -3.2% compound annual growth rate (CAGR), from $15.23M to $12.94M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.